We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Fluorescent-Polymer Sensor Test Detects Liver Fibrosis

By LabMedica International staff writers
Posted on 05 Jun 2018
A novel method has been developed that can detect liver fibrosis from a blood sample in 30-45 minutes.

Liver disease is the fifth most common cause of premature death in the Western world, with the irreversible damage caused by fibrosis, and ultimately cirrhosis, a primary driver of mortality. More...
Early detection of fibrosis would facilitate treatment of the underlying liver disease to limit progression. Unfortunately, most cases of liver disease are diagnosed late, with current strategies reliant on invasive biopsy or fragile laboratory‐based antibody technologies.

To upgrade the laboratory's ability to detect liver fibrosis, investigators at the University of Massachusetts (Amherst, USA) and University College London (United Kingdom) developed a robust, fully synthetic fluorescent‐polymer sensor array. The array uses polymers coated with fluorescent dyes that bind to blood proteins based on specific chemical processes. The dyes vary in brightness and color, presenting different signatures or blood protein patterns.

The sensor procedure, which was completed in only about 45 minutes, was evaluated by comparing results from 65 finger-prick volume blood samples taken from three balanced groups of healthy patients and from a group with early-stage and late-stage fibrosis patients. The test distinguished fibrotic samples from healthy blood 80% of the time, reaching the standard threshold of clinical relevance on a widely used metric and comparable to existing methods of diagnosing and monitoring fibrosis. The test distinguished between mild-moderate fibrosis and severe fibrosis 60% of the time.

"This platform provides a simple and inexpensive way of diagnosing disease with potential for both personal health monitoring and applications in developing parts of the world," said senior author Dr. Vincent Rotello, professor of chemistry at the University of Massachusetts. "A key feature of this sensing strategy is that it is not disease-specific, so it is applicable to a wide spectrum of conditions, which opens up the possibility of diagnostic systems that can track health status, providing both disease detection and monitoring wellness."

Use of the fluorescent‐polymer sensor array was described in the May 24, 2018, online edition of the journal Advanced Materials.

Related Links:
University of Massachusetts
University College London


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.